| DB ID | MyCo_6479 |
| Title | Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis |
| Year | 2023 |
| PMID | 37015988 |
| Fungal Diseases involved | Allergic bronchopulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | This study was approved by the Institutional Review Board for clinical research of the Tokai University Hospital (#18R-290 and #22R-161) and carried out according to the principles embodied in the Declaration of Helsinki of 1965, as revised in Brazil in 2013. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | Anti-IL-5/IL-5Rα |
| Biomarker Full Name | Anti-Interleukin-5/Interleukin-5 receptor α chain (Rα) |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Japan |
| Cohort | Twenty-nine patients with ABPM treated with anti-IL-5/IL-5Rα mAbs, including 22 (76%) women with a median age of 63 years, were registered from 15 clinical centers in Japan. |
| Cohort No. | 29 |
| Age Group | 63 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Analytic |
| Analysis Method | Radiographic assessment |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Radiographic assessment |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
